NCT00991861View on ClinicalTrials.gov

Efficacy and Safety Study of LAS41007 in the Treatment of Actinic Keratosis

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

February 28, 2010

Study Completion Date

February 28, 2010

Conditions
Actinic Keratosis
Interventions
DRUG

LAS41007 o.d.

Once daily, topical application

DRUG

LAS41007 b.i.d.

Twice daily, topical application

DRUG

LAS106521

Twice daily, topical application

Trial Locations (1)

Unknown

Investigational Site, Hamburg

Sponsors

Lead Sponsor

Almirall, S.A.
All Listed Sponsors
lead

Almirall, S.A.

INDUSTRY